ArticleReproductive sciences (Thousand Oaks, Calif.)2025
Luteinizing Hormone Preserves Oocyte-Granulosa Cell Communication in Growing Follicles Exposed to Chemotherapy with Alkylating Agents at the Primordial Stage in a Mouse Model.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Fatty Acid Amide Hydrolase Signaling and Ovarian Disorders: From Molecular Mechanism to Clinical Significance.Molecules (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Reciprocal communication between the oocyte and adjacent granulosa cells (GC) throughout folliculogenesis can be disrupted by chemotherapy. Recent work suggests that luteinizing hormone (LH) may protect the quality of metaphase-II oocytes derived from primordial follicles exposed to chemotherapy in mice. Here, we showed that LH improved the follicular yield of CD1 mice ovaries exposed to alkylating chemotherapy by primarily protecting the smallest follicles, i.e., the primordial and primary populations. LH treatment reverted the chemotherapy-induced impairment of oocyte-GC communication at the gene and protein levels in secondary and later-stage follicles exposed to alkylating chemotherapy at the primordial phase by preserving the germ and somatic cell compartments. These changes are follicle-specific, as supported by the absence of differences in ovarian stroma. LH also restored the immunofluorescence signal for cell junction proteins Cx37, E-Cad and Cx43, and for oocyte-secreted factors GDF9 and BMP15. The alteration of signal intensity associated with these cell junction proteins and oocyte-secreted factors by chemotherapy was detected beyond the secondary stage, suggesting that attenuation of oocyte-GC crosstalk might happen during the primary-secondary transition. Our results suggest that LH-treated primordial follicles retain the ability to properly establish oocyte-GC interactions and crosstalk during follicular growth representing a novel mechanism triggered by LH that would explain the reported protective effects of LH on oocyte quality and female fertility. However, this is an animal model study that should be validated in larger studies with human samples.
Indexed as
Identifiers
40770600What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.